Low-molecular-weight-heparin in radial artery occlusion treatment: the LOW-RAO randomized study.
Matthaios DidagelosAreti PagiantzaThomas ZegkosChristos PapanastasiouKonstantina ZarraVasileios AngelopoulosAntonios KouparanisEmmanouela PeteinidouGeorge SianosHaralambos KarvounisAntonios ZiakasPublished in: Future cardiology (2021)
Radial artery occlusion (RAO) is the commonest complication of transradial catheterization. There is no evidence-based therapy, in the frame of a randomized control study, for the treatment of RAO. The purpose of the LOW-RAO study is to question the hypothesis if low-molecular-weight heparin is effective in the treatment of RAO after transradial coronary catheterization (both angiography and percutaneous coronary intervention). It is a prospective, open label, randomized controlled trial that will randomize 60 patients with RAO, irrespective of symptoms, into two groups, one receiving anticoagulation with low-molecular-weight heparin and the other receiving no treatment. The primary end point is improvement in radial artery patency rate at 4 weeks after the procedure. Trial registration number: NCT04196309 (ClinicalTrials.gov).
Keyphrases
- percutaneous coronary intervention
- randomized controlled trial
- venous thromboembolism
- coronary artery disease
- open label
- clinical trial
- study protocol
- heart failure
- computed tomography
- ultrasound guided
- acute coronary syndrome
- optical coherence tomography
- st segment elevation myocardial infarction
- squamous cell carcinoma
- mesenchymal stem cells
- combination therapy
- phase ii
- depressive symptoms
- aortic valve
- phase iii
- st elevation myocardial infarction
- sleep quality
- replacement therapy
- preterm birth
- rectal cancer
- aortic stenosis